Leerink lifts Elanco Animal Health stock target to USD 34.00

Published on 10/15/2026 at 22:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elanco posted USD 1.37 billion revenue in the second quarter of 2026, up 10.20 percent year over year. Elanco stock costs EUR 21.01 on October 15, 2026.

Analyst target and earnings

Leerink Partners raised its Elanco target from USD 30.00 to USD 34.00 on October 2, 2026.
Elanco reported USD 1.37 billion revenue in the second quarter of 2026, up 10.20 percent year over year.
Elanco stock trades at EUR 21.01 at 10:16 p.m. CEST at Lang & Schwarz on October 15, 2026.
Elanco's next results are scheduled for November 6, 2026.

ELAN, US28414H1032, Illustration mit AI erstellt.

Leerink Partners raised its Elanco Animal Health target from USD 30.00 to USD 34.00 on October 2, 2026, according to Futu. The target is 44.43 percent above Elanco's USD 23.54 home-market price on October 15, 2026. Elanco stock was trading at EUR 21.01 at Lang & Schwarz on October 15, 2026 at 10:16 p.m. CEST.

Revenue growth sets the base

Elanco reported USD 1.37 billion revenue in the second quarter of 2026, up 10.20 percent from the year-ago quarter, while net income attributable to common shareholders reached USD 54.00 million. Yahoo Finance reported that the revenue figure exceeded analysts' expectations by 4.20 percent.

Price position and valuation

Elanco's USD 19.40 to USD 27.98 52-week range places the current USD 23.54 quote 15.89 percent below the high. The company recorded USD 6.65 million shares in volume on October 15, 2026, versus an average of USD 6.18 million shares. Its market capitalization was USD 11.8 billion, and its trailing price-to-earnings ratio was minus 58.84.

What comes next

Elanco's next financial results are scheduled for November 6, 2026, according to PR Newswire. The date gives investors a defined checkpoint for judging whether second-quarter growth is carrying into the second half.

Comparison with peers

Elanco: plus 4.39 percent, P/E minus 58.84, market capitalization USD 11.8 billion
Zoetis (NYSE, USD): plus 4.17 percent, P/E 12.93, market capitalization USD 32.4 billion
IDEXX Laboratories (NASDAQ, USD): plus 3.43 percent, P/E 38.75, market capitalization USD 43.1 billion

Stock stays below its yearly high

Elanco's valuation remains shaped by the contrast between its second-quarter revenue growth and negative trailing earnings. The USD 4.00 increase in the Leerink target also leaves a measurable gap between the analyst view and the latest home-market quote.

Elanco was trading at EUR 21.01 at Lang & Schwarz on October 15, 2026 at 10:16 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Elanco Animal Health stock.